Seeking Alpha

Trouble may be brewing for Osiris after MiMedx FDA letter: Feuerstein

MiMedx's (MDXG) recent issues with the FDA "might portend trouble" for Osiris Therapeutics (OSIR), theStreet's Adam Feuerstein writes, in response to a reader's e-mail inquiry.

MDXG "believed it could sell AmnioFix and EpiFix as HCT/P products" but the FDA apparently considers them to be "biologic products" which means they "must undergo review for efficacy and safety just like other drugs," Feuerstein says.

The problem for OSIR: "Grafix and Ovation are HCT/P products [and] MDXG is  raising a stink about competitors, insisting FDA take a closer look at their products which may also violate the HCT/P manufacturing guidelines."

A little less than a month ago, OSIR shares took off after Grafix performed well in a study of patients with diabetic foot ulcers.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs